Case Report
Administration of Alpha-1 Antitrypsin in Haemodialysis
| Martin-Gomez MA*, Martinez de la Plata E, Hidalgo Rico MA, Palacios Gomez ME and Garcia-Marcos S | |
| Units Nephrology and Neumologia, Public Enterprise Hospital de Poniente, Almeria, Spain | |
| *Corresponding Author : | Martin-Gomez MA Units Nephrology and Neumologia Public Enterprise Hospital de Poniente Almeria, Spain Tel: 677081239 E-mail: doritamg@gmail.com |
| Received September 14, 2015; Accepted December 15, 2015; Published December 18, 2015 | |
| Citation:Martin-Gomez MA, Martinez de la Plata E, Hidalgo Rico MA, Palacios Gomez ME, Garcia-Marcos S (2015) Administration of Alpha-1 Antitrypsin in Haemodialysis. Kidney Disord Clin Pract 1:102. doi:10.4172/kdc.1000102 | |
| Copyright: © 2015 Martin-Gomez MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
The deficit of alpha-1-antitrypsin (AATD) is the most common potentially fatal hereditary disease in adulthood, causing the onset of emphysema, various liver diseases and favouring the development and progression of tumours and systemic vasculitis. Treatment is replacement rate. The dosing schedule alpha1-antitrypsin (α-1AT) has been modified over time by infraestrutura centers dedicated to it. In the beginning, a weekly administration agreed, but given the saturation of the hospitals and the deterioration of the quality of life of patients having to go to hospital every week, it was decided to increase the interval to every 15-21 days.
